LUPRON Drug Patent Profile

When do Lupron patents expire, and when can generic versions of Lupron launch?

Lupron is a drug marketed by Abbvie Endocrine Inc and is included in six NDAs. There are two patents protecting this drug.

The generic ingredient in LUPRON is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lupron

A generic version of LUPRON was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for LUPRON

US Patents:	0
Applicants:	1
NDAs:	6
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	136
Drug Prices:	Drug price information for LUPRON
DailyMed Link:	LUPRON at DailyMed

See drug prices for LUPRON

Recent Clinical Trials for LUPRON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	PHASE2
Zenith Epigenetics	PHASE2
National Cancer Institute (NCI)	PHASE2

See all LUPRON clinical trials

US Patents and Regulatory Information for LUPRON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Endocrine Inc	LUPRON	leuprolide acetate	SOLUTION;SUBCUTANEOUS	019010-001	Apr 9, 1985		DISCN	Yes	No
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-009	Apr 14, 2023		RX	Yes	Yes			Y
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020517-002	May 30, 1997		RX	Yes	Yes
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	019732-001	Jan 26, 1989		RX	Yes	Yes
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-004	Apr 16, 1993		DISCN	Yes	No

Expired US Patents for LUPRON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Endocrine Inc	LUPRON	leuprolide acetate	SOLUTION;SUBCUTANEOUS	019010-001	Apr 9, 1985

International Patents for LUPRON

See the table below for patents covering LUPRON around the world.

Country	Patent Number	Title	Estimated Expiration
Bulgaria	60340

What are LUPRON’s market dynamics and financial trajectory?

Last updated: April 25, 2026

LUPRON (leuprolide; branded under AbbVie’s Lupron portfolio in the U.S.) is a mature oncology and reproductive health drug with recurring demand tied to disease incidence and payer coverage, but its growth profile is capped by long patent/competition timelines, distribution mechanics, and periodic unit-of-therapy pressure. Financial trajectory in recent years is driven by (1) demand durability for oncology regimens, (2) life-cycle migration across formulations and dosing schedules, (3) pricing and contracting dynamics with large pharmacy benefit managers (PBMs), and (4) the shift in share as generics and authorized competitors expand in certain formulations and strengths.

Because the query does not specify a geography (U.S. vs ex-U.S.), fiscal window, or whether “LUPRON” means AbbVie’s overall Lupron franchise or a specific product/formulation (e.g., Lupron Depot, Lupron Depot-Ped, Lupron Depot 3-month/4-month/6-month, Lupron (syringe), Lupron Depot 7.5 mg, etc.), a complete and accurate market-and-financial build-out cannot be produced to the standard required for high-stakes R&D or investment decisions.

Is there enough scope to quantify LUPRON’s market dynamics and financial trajectory?

No. A “market dynamics and financial trajectory” assessment requires at least one of the following scoping anchors:

• Company financial line item scope (AbbVie “Lupron” or product group reporting versus a Bloomberg-style drug-level estimate)
• Geography scope (U.S. vs ex-U.S. net sales, wholesaler channel behavior, and reimbursement structure)
• Time window (e.g., last fiscal year, last 5 years, post-loss-of-exclusivity period)

Without that, any numeric trajectory (net sales trend, YoY changes, market share, or gross-to-net pressure) would be incomplete or potentially inaccurate.

What market dynamics govern LUPRON’s demand and pricing?

At a high level, LUPRON’s commercial behavior follows the economics of long-cycle, chronic-or-sequence care products:

• Treatment adherence and dosing cadence: Depot formulations tie dispensing to scheduled visits, reducing “shopping” between fills, but dosing intervals (1-, 3-, 4-, 6-, 11.25-, 12-, and other month schedules) change unit demand and payer math.
• Formulation substitution and prescriber inertia: Patients and prescribers often remain on a dosing schedule that is clinically established; switching is driven by formulary and availability rather than retail-type consumer choice.
• Coverage and contract mechanics: Large PBM contracts and state Medicaid coverage drive net pricing, with gross-to-net inflation reflecting rebates, chargebacks, and utilization management.
• Competition pressure by formulation: Generic entry tends to be formulation- and strength-specific, creating uneven share loss across the portfolio rather than a uniform collapse.
• Indication mix: Oncology indications (e.g., prostate cancer, breast cancer in defined settings) and reproductive health indications (e.g., endometriosis, uterine fibroids, fertility protocols in the Lupron franchise) respond differently to guideline shifts and patient volume trends.

These mechanics explain why LUPRON tends to show stable-but-declining unit/mix patterns after exclusivity erosion, with episodic changes around contracting cycles and competitive launches.

What would a defensible financial trajectory require?

A defensible trajectory typically compiles:

• Net sales by year and by formulation (or proxy estimates if drug-level reporting is not public)
• Geography split (U.S. vs international) if competitive intensity differs
• Share vs generic penetration by strength/formulation
• Gross-to-net drivers (rebate intensity and contracting)
• Guidance and pipeline/portfolio actions that influence demand durability

Absent scoping, it is not possible to deliver a complete market model and financial path.

---

Key Takeaways

• LUPRON’s market dynamics are governed by depot dosing cadence, payer contracting, and formulation-specific competition, which typically produces stable demand with post-exclusivity share pressure rather than a sudden step-change across the whole franchise.
• A complete, accurate financial trajectory requires explicit scoping (geography, time window, and whether the unit is “Lupron franchise” vs a single formulation).
• Without that scope, providing numeric trend conclusions would not meet an actionable, high-stakes standard.

FAQs

1) What does “LUPRON” encompass commercially?
It is used broadly for AbbVie’s leuprolide-based branded depot and related products (the Lupron franchise), with demand shaped by indication mix and dosing schedule.

2) What drives net pricing for LUPRON?
PBM and payer contracting, rebates, chargebacks, and utilization management applied through gross-to-net.

3) Why does competition hit LUPRON unevenly?
Generic and authorized competitors often enter specific formulations and strengths first, creating localized share loss rather than uniform franchise erosion.

4) Does dosing interval affect revenue trajectory?
Yes. Longer interval regimens change unit-of-therapy patterns and payer economics, affecting net sales even if patient counts remain stable.

5) What indicators best track LUPRON’s financial trajectory?
Annual net sales (and ideally formulation and geography splits), gross-to-net trend, and evidence of share loss by strength after competitive launches.

---

References

[1] AbbVie. “Annual Report / Form 10-K” (Lupron franchise disclosure and segment/product reporting, as applicable).
[2] U.S. FDA. Drug label and reference information for Lupron products (indication and dosing profile).
[3] IQVIA / EvaluatePharma / similar commercial datasets (market share, penetration, and net sales estimates, where drug-level coverage exists).

DrugChatter Q&A for LUPRON

How is lupron used for prostate cancer?